Australian respiratory technology company Rhinomed has entered into a distribution and supply agreement with The Linde Group and its Australian subsidiary BOC Limited.

BOC will manage logistics and distribute Rhinomed’s breathing technologies, Mute and Turbine, in the Australian and New Zealand markets.

Rhinomed will ship product directly from its Hong Kong warehouse to BOC’s logistics centre in Sydney. Under the arrangement, BOC will fulfill and supply all of Rhinomed’s existing contracts within Australia—covering the existing 700 pharmacies currently stocking the product.

BOC brings an extensive and experienced sales force to support the growing uptake of Rhinomed’s products in the region. Mute complements BOC’s current sleep equipment offering, which includes CPAP masks and supplies and in-home sleep studies.

Colin Smith, head of healthcare, BOC Limited says in a release, “BOC is proud to partner with Rhinomed as their distributor for Mute and Turbine across Australia and New Zealand. As a leader in the Australian and New Zealand sleep markets, BOC has been providing quality sleep therapy to patients in Australia for more than ten years.”

BOC Limited is part of The Linde Group, a global gas, healthcare, and engineering company, operating in over 70 countries with an annual turnover of more than €17 billion. BOC provides pharmaceutical and medical products and services across hospitals, clinics, intermediate care centers, aged care facilities, GPs, emergency centers, convenience stores, service stations, and patients’ homes. The Linde Group operates in the United States through its subsidiary Lincare. Lincare provides services and equipment, operating from approximately 1,000 locations in 48 states and Canada.

“The relationship with The Linde Group and its subsidiary BOC further cements Rhinomed’s strategy of positioning Mute as the front-line solution for millions of people as they enter the sleep solutions market. This agreement will deliver significant scale to Mute’s presence in the Australian and New Zealand sleep market,” says RhInomed CEO Michael Johnson.

Mute is a nasal stent designed to hold open and individually dilate the nasal airway, alleviating the effect of nasal obstruction, to improve nasal breathing and reduce snoring. It is currently available in leading pharmacy and sleep clinics in the United States, Canada, the UK, and Australia, as well as via online platforms.

| A Linde Group release | Dec 9, 2016 |